Monthly Archives: September 2011
By Ben Comer | Published: September 28, 2011
R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
By Ben Comer | Published: September 27, 2011
While Big Pharma frets over the costs and risks associated with exploratory endpoints in the clinic and the vagaries of companion diagnostic reimbursement, non-profit organizations like the Multiple Myeloma Research Foundation (MMRF) are stepping in to provide pharmacogenomic research for the next generation of cancer drugs.
By Ben Comer | Published: September 23, 2011
Now that 90% of the top 43 countries for drug sales have instituted “significant” cost containment measures, it’s more important than ever to give payers the rest of the story, according to a Pfizer executive.
By Guest Blogger | Published: September 21, 2011
Deals don’t need science to be a success By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will […]
By Ben Comer | Published: September 20, 2011
Amid the flurry of cost-cutting proposals aimed at guiding the Joint Select Committee on Deficit Reduction’s (Super Committee) budgetary blade, the Obama Administration has now weighed in with a proposal to cut $248 billion from Medicare spending over ten years, and $73 billion in Medicaid and other health-related spending. The Obama plan, which would increase […]